Alpha Family Trust Buys Shares of 900 Becton, Dickinson and Company (NYSE:BDX)

Alpha Family Trust bought a new stake in shares of Becton, Dickinson and Company (NYSE:BDX) during the 3rd quarter, HoldingsChannel reports. The institutional investor bought 900 shares of the medical instruments supplier’s stock, valued at approximately $217,000.

Other institutional investors also recently bought and sold shares of the company. Livelsberger Financial Advisory bought a new position in Becton, Dickinson and Company during the third quarter valued at about $26,000. Ashton Thomas Securities LLC bought a new position in Becton, Dickinson and Company during the third quarter valued at about $33,000. Tompkins Financial Corp raised its holdings in Becton, Dickinson and Company by 44.2% during the third quarter. Tompkins Financial Corp now owns 150 shares of the medical instruments supplier’s stock valued at $36,000 after buying an additional 46 shares in the last quarter. Sound Income Strategies LLC raised its holdings in Becton, Dickinson and Company by 35.8% during the third quarter. Sound Income Strategies LLC now owns 167 shares of the medical instruments supplier’s stock valued at $40,000 after buying an additional 44 shares in the last quarter. Finally, Opal Wealth Advisors LLC bought a new position in shares of Becton, Dickinson and Company in the second quarter worth about $45,000. 86.97% of the stock is currently owned by institutional investors.

Becton, Dickinson and Company Stock Down 0.9 %

BDX stock opened at $225.15 on Friday. Becton, Dickinson and Company has a twelve month low of $218.75 and a twelve month high of $249.89. The company has a market cap of $65.08 billion, a PE ratio of 37.90, a price-to-earnings-growth ratio of 1.68 and a beta of 0.43. The business’s 50-day simple moving average is $236.30 and its 200 day simple moving average is $234.99. The company has a quick ratio of 0.74, a current ratio of 1.17 and a debt-to-equity ratio of 0.69.

Becton, Dickinson and Company (NYSE:BDX) last released its earnings results on Thursday, November 7th. The medical instruments supplier reported $3.81 earnings per share for the quarter, topping analysts’ consensus estimates of $3.77 by $0.04. The business had revenue of $5.44 billion for the quarter, compared to the consensus estimate of $5.38 billion. Becton, Dickinson and Company had a return on equity of 14.89% and a net margin of 8.55%. The firm’s revenue for the quarter was up 6.9% compared to the same quarter last year. During the same period last year, the business earned $3.42 earnings per share. On average, research analysts anticipate that Becton, Dickinson and Company will post 14.43 earnings per share for the current year.

Becton, Dickinson and Company Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 31st. Shareholders of record on Monday, December 9th will be issued a dividend of $1.04 per share. This represents a $4.16 dividend on an annualized basis and a yield of 1.85%. This is an increase from Becton, Dickinson and Company’s previous quarterly dividend of $0.95. The ex-dividend date is Monday, December 9th. Becton, Dickinson and Company’s payout ratio is presently 63.97%.

Analysts Set New Price Targets

BDX has been the topic of a number of recent analyst reports. Citigroup upgraded Becton, Dickinson and Company from a “neutral” rating to a “buy” rating and lifted their price objective for the stock from $255.00 to $275.00 in a research note on Tuesday, October 1st. StockNews.com upgraded Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a research note on Thursday, August 8th. Evercore ISI lifted their price objective on Becton, Dickinson and Company from $286.00 to $290.00 and gave the stock an “outperform” rating in a research note on Tuesday, October 1st. Raymond James dropped their price objective on Becton, Dickinson and Company from $275.00 to $270.00 and set an “outperform” rating on the stock in a research note on Friday, August 2nd. Finally, Stifel Nicolaus lifted their price objective on Becton, Dickinson and Company from $270.00 to $280.00 and gave the stock a “buy” rating in a research note on Friday, July 26th. Eight equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Becton, Dickinson and Company currently has a consensus rating of “Buy” and a consensus target price of $283.00.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.